LH Drugs That Distort This Test: What Raises, Lowers, or Fakes Your Luteinizing Hormone Result

What LH Is and Why the Test Matters

Luteinizing hormone is a glycoprotein secreted by gonadotroph cells in the anterior pituitary. It travels through the bloodstream to the gonads, triggering testosterone synthesis in Leydig cells (men) and triggering ovulation plus progesterone production from the corpus luteum (women). The test matters because LH, read alongside FSH and sex steroids, tells you whether a hormone deficiency originates in the pituitary or the gonads themselves. That single distinction separates primary hypogonadism (high LH, failing gonads) from secondary hypogonadism (low LH, pituitary or hypothalamic cause), and the two conditions require entirely different treatments [1].

How the Hypothalamic-Pituitary-Gonadal Axis Controls LH

The hypothalamus fires GnRH pulses roughly every 60 to 90 minutes. Each pulse primes the pituitary to release a burst of LH and FSH. Testosterone and estradiol feed back negatively onto both the hypothalamus and the pituitary, slowing GnRH pulse frequency and blunting LH output. Any drug that mimics sex steroids, floods GnRH receptors, or disrupts dopamine or kisspeptin signaling will shift LH off its baseline value [2].

Why Pulse Frequency Matters for Sampling

Because LH is secreted in pulses, a single random draw carries a coefficient of variation of roughly 25 to 30%. The Endocrine Society's 2018 hypogonadism guideline recommends collecting LH as part of a morning draw (7 to 10 AM), when the HPG axis is most active in men, and on days 2 to 4 of the menstrual cycle for women when baseline gonadotropin levels are most interpretable [1].

Normal LH Ranges and How to Read Them

Reference intervals differ by sex, menstrual phase, and assay platform. The ranges below are drawn from Endocrine Society and AACE guidance; your specific laboratory may differ slightly depending on the immunoassay used [3].

Men

Adult males (ages 18 to 70) show LH between 1.7 and 8.6 IU/L on most third-generation immunoassays. Values above 9 IU/L in a man with low or low-normal testosterone suggest primary (testicular) failure. Values below 1.5 IU/L in a symptomatic man point toward secondary hypogonadism and warrant pituitary imaging plus a full pituitary panel [1].

Women

Interpretation requires knowing cycle day. Follicular phase: 2.4 to 12.6 IU/L. Preovulatory surge: 14 to 95 IU/L. Luteal phase: 1.0 to 11.4 IU/L. Postmenopausal women typically run 15 to 65 IU/L, reflecting loss of ovarian negative feedback. Polycystic ovary syndrome (PCOS) frequently produces an LH-to-FSH ratio above 2:1 in the early follicular phase, a finding that, while not diagnostic on its own, prompted the 2023 international PCOS evidence-based guidelines to include gonadotropin assessment in the diagnostic workup [4].

Drugs That Suppress LH

Many of the most widely prescribed hormone-related medications drive LH into the floor. The mechanism varies, but the common endpoint is reduced GnRH pulsatility or direct pituitary suppression.

Testosterone and Anabolic Androgens

Exogenous testosterone is the single most common drug cause of suppressed LH seen in telehealth practice. Within 3 to 7 days of starting testosterone cypionate 100 mg/week, LH falls toward undetectable. By week 4, most men on standard TRT doses show LH values <0.5 IU/L [5]. The suppression is dose-dependent and reflects negative feedback at both the hypothalamus and the pituitary. Synthetic anabolic steroids (nandrolone, stanozolol, oxandrolone) produce the same suppression even at lower doses, because many are non-aromatizable or only partially aromatizable yet still bind androgen receptors in the hypothalamus [6].

A man presenting with LH of 0.2 IU/L and total testosterone of 900 ng/dL is not hypogonadal. He is on exogenous androgens. That LH result must be interpreted against a careful medication history before any diagnosis is applied.

Estrogens and Progestins

Oral contraceptives combine ethinyl estradiol with a progestin, suppressing LH surge with 99%+ efficacy at standard doses. This is the mechanism of ovulation prevention. Women who stop oral contraceptives may take 4 to 12 weeks to recover baseline LH pulsatility; the Endocrine Society notes that gonadotropin testing should generally be deferred until two to three natural cycles have passed after discontinuation [1].

Hormone therapy in postmenopausal women using estradiol patches or pills also suppresses LH, though not to the complete degree seen with oral contraceptives. A postmenopausal woman on 0.1 mg/day estradiol patch may show LH values of 10 to 25 IU/L rather than the expected 30 to 65 IU/L, which could obscure the menopausal diagnosis if the clinician forgets to ask about HRT use [7].

GnRH Agonists: The Flare-Then-Crash Pattern

Leuprolide (Lupron), buserelin, and triptorelin are used in prostate cancer, endometriosis, uterine fibroids, central precocious puberty, and gender-affirming care. Their LH effects follow a counterintuitive two-phase pattern.

Phase 1 (days 1 to 7): Continuous GnRH receptor stimulation causes an initial LH surge, sometimes 3 to 10 times baseline. This "flare" can temporarily worsen testosterone-dependent conditions and is why antiandrogen co-administration is standard practice at leuprolide initiation in prostate cancer patients.

Phase 2 (days 21 to 28 onward): Continuous, non-pulsatile GnRH receptor occupancy downregulates receptor expression. LH falls to <1 IU/L. Testosterone drops to castrate levels (<50 ng/dL) by weeks 3 to 4 [8]. A patient on month 3 of leuprolide therapy who shows LH of 0.3 IU/L is responding normally. That result is not diagnostic of pituitary disease in this context.

GnRH Antagonists

Degarelix and relugolix block GnRH receptors directly, skipping the initial flare. LH suppression occurs within 3 days of the first dose. The HERO trial (N=934) showed relugolix achieved castrate testosterone levels in 96.7% of men with advanced prostate cancer by day 15, faster than leuprolide [9]. LH on relugolix runs <0.5 IU/L at steady state.

Opioids

Opioid-induced hypogonadism is a well-documented but under-recognized phenomenon. Opioids act on mu-receptors in the hypothalamus, reducing GnRH pulse frequency and amplitude. A meta-analysis published in the Journal of Clinical Endocrinology and Metabolism found that chronic opioid use suppressed LH in 86% of male users and 52% of female users studied [10]. The effect is dose-dependent and seen with both short-acting opioids (oxycodone, hydrocodone) and long-acting formulations (methadone, extended-release morphine). Methadone may be particularly potent at HPG suppression relative to analgesic dose.

Clinicians seeing low LH in a patient on opioid therapy should document opioid dose in morphine milligram equivalents (MME) before attributing the finding to pituitary disease. The 2019 Endocrine Society guideline on male hypogonadism specifically lists opioids as a reversible cause of secondary hypogonadism [1].

Antipsychotics and Prolactin-Raising Drugs

Dopamine antagonist antipsychotics (haloperidol, risperidone, olanzapine, metoclopramide) raise prolactin by blocking tuberoinfundibular dopamine. Elevated prolactin then suppresses GnRH pulsatility. LH values of 0.5 to 2.5 IU/L with concurrent prolactin above 40 ng/mL in a patient on risperidone represents drug effect, not a pituitary adenoma, until prolactin remains elevated after drug discontinuation [11].

Glucocorticoids

High-dose or long-term glucocorticoid therapy (prednisone >15 mg/day for >3 months) suppresses the HPG axis at the hypothalamic level by inhibiting GnRH secretion. LH values below 2 IU/L have been documented in men on long-term corticosteroid therapy for autoimmune disease, correlating with low testosterone and reduced bone density [12].

Drugs That Raise LH

A smaller but clinically important group of drugs push LH upward by blocking negative feedback or directly stimulating gonadotropin release.

Clomiphene Citrate

Clomiphene is a selective estrogen receptor modulator (SERM) that blocks estrogen receptors in the hypothalamus. The hypothalamus interprets the blockade as low estrogen and increases GnRH pulse frequency. LH rises 1.5 to 3 times baseline within 5 to 10 days of starting clomiphene 25 to 50 mg/day. In men with secondary hypogonadism, this LH rise drives intratesticular testosterone production upward while preserving spermatogenesis, which is why clomiphene is preferred over TRT for hypogonadal men who want to maintain fertility [13].

A randomized controlled trial by Ramasamy et al. (2014, N=140) showed that clomiphene citrate 25 mg every other day raised serum testosterone from a mean of 232 ng/dL to 463 ng/dL at 3 months, with LH rising from 4.2 to 7.8 IU/L [14].

Letrozole and Other Aromatase Inhibitors

Aromatase inhibitors (letrozole, anastrozole) block the conversion of testosterone to estradiol. Lower estradiol reduces negative feedback on the hypothalamus and pituitary, allowing LH (and FSH) to rise. In men with hypogonadism caused by excess aromatase activity or obesity-driven high estradiol, letrozole can restore LH into the normal range while raising testosterone [15].

In women, letrozole 2.5 to 7.5 mg given on cycle days 3 to 7 is the first-line ovulation induction agent per the 2023 ASRM guideline for anovulatory infertility associated with PCOS, generating a controlled LH surge and monofollicular development more reliably than clomiphene [16].

Naltrexone

The opioid antagonist naltrexone, used in opioid use disorder and alcohol use disorder, removes opioid-mediated GnRH suppression. At low doses (1.5 to 4.5 mg, so-called "low-dose naltrexone"), some patients with opioid-induced hypogonadism see LH recovery within 4 to 8 weeks of starting therapy [17]. This is a reversible normalization, not a pharmacological stimulation above baseline.

Kisspeptin Analogs (Investigational)

Kisspeptin-54 and kisspeptin-10 are hypothalamic peptides that directly stimulate GnRH neurons. Intravenous kisspeptin-54 at 1 nmol/kg raises LH 10 to 15-fold within 30 minutes in healthy men and women. Phase 2 trials are evaluating subcutaneous formulations for hypothalamic amenorrhea and male hypogonadism [18]. These agents are not yet FDA-approved, but patients enrolled in clinical trials will show very high LH values that could be misread as a pathological LH surge if the treating clinician is not informed of trial participation.

Assay Interference: Drugs and Supplements That Fake an LH Result

Not every abnormal LH value reflects a true change in hormone concentration. Some substances interfere with the immunoassay chemistry itself.

Biotin (Vitamin B7)

Biotin supplementation above 5 mg/day (doses common in hair and nail supplements) interferes with streptavidin-biotin immunoassay platforms, which are used by many major clinical labs for LH measurement. The interference typically causes falsely low LH results (and falsely low TSH, FT4, FSH) on competitive immunoassay platforms, while causing falsely elevated results on sandwich immunoassays. The FDA issued a safety communication in 2019 specifically warning about biotin interference with hormone immunoassays [19]. Patients should stop biotin-containing supplements at least 72 hours before LH testing.

Heterophile Antibodies

Patients with high levels of heterophile antibodies (from animal exposure, IVIG therapy, or certain autoimmune conditions) may show spuriously elevated LH values on immunoassay. Serial dilution testing or use of a heterophile antibody blocking tube can unmask this artifact. Clinicians should suspect assay interference when LH is markedly elevated but the clinical picture (normal menstrual cycles, normal testosterone, no menopausal symptoms) does not fit [20].

Human Chorionic Gonadotropin (hCG) Cross-Reactivity

HCG shares the alpha-subunit with LH and has significant structural homology in the beta-subunit. Older first-generation LH assays showed up to 40% cross-reactivity with hCG. Third-generation immunoassays have reduced but not eliminated this. A patient on hCG therapy (for hypogonadism, fertility support, or weight loss protocols) may show falsely elevated LH values on some platforms. A patient who is pregnant and unaware will also show elevated apparent LH. Clinical context and a concurrent beta-hCG measurement resolve the ambiguity [21].

Drugs That Have Minimal Direct Effect on LH

Some medications are commonly assumed to distort LH but actually have limited direct effect at standard therapeutic doses. Metformin does not directly alter LH, though it may modestly reduce LH pulse amplitude in women with PCOS via insulin sensitization over 3 to 6 months [22]. GLP-1 receptor agonists such as semaglutide produce weight loss that secondarily improves LH pulsatility in obese women with anovulation, but the effect is indirect and mediated through reduced adipose tissue aromatase activity rather than direct HPG action [23]. SSRI antidepressants at standard doses generally do not raise prolactin to levels that suppress LH, with the notable exception of high-dose paroxetine in some patients.

How to Interpret LH When a Patient Is on Multiple Drugs

A Practical Medication Reconciliation Framework

Before interpreting any LH result, document:

1. Current exogenous androgens or estrogens (dose, formulation, duration)
2. Current GnRH agonist or antagonist therapy
3. Opioid use (drug name, daily MME equivalent)
4. Antipsychotics or prolactin-raising drugs (with concurrent prolactin level)
5. Biotin supplement dose and timing relative to the blood draw
6. HCG use or pregnancy status

If any item on that list is present, the LH result must be interpreted in context of the drug effect before a diagnosis of hypogonadism, premature ovarian insufficiency, or pituitary disease is made.

When to Retest After Drug Washout

The Endocrine Society's 2018 guideline on male hypogonadism recommends confirming hypogonadism with a second morning testosterone and LH after stopping or adjusting any medication known to suppress gonadotropins, allowing sufficient time for clearance: at least 4 to 6 weeks after stopping testosterone esters, 8 to 12 weeks after stopping depot leuprolide, and 1 to 2 weeks after stopping oral contraceptives in younger women [1].

Distinguishing Primary from Secondary Hypogonadism on a Medicated Patient

If a patient has been off all suppressive medications for the appropriate washout interval and LH remains below 1.5 IU/L with low testosterone, secondary hypogonadism is the working diagnosis pending pituitary MRI and full anterior pituitary panel (ACTH, GH, TSH, prolactin). If LH is above 9 to 10 IU/L with low testosterone after washout, primary gonadal failure is likely and karyotype (in younger men) or autoimmune panel (in women <40) should follow [1,3].

LH Testing in Specific Clinical Contexts

Testosterone Replacement Therapy Monitoring

LH should not be used to monitor TRT response. Exogenous testosterone suppresses LH to undetectable levels by design. The relevant monitoring labs on TRT are total testosterone (trough, target 400 to 700 ng/dL per most TRT protocols), hematocrit, PSA, and estradiol. LH on TRT will show <0.5 IU/L in virtually all compliant patients; that value carries no diagnostic information about therapy adequacy [5].

Fertility Evaluation

In men being evaluated for infertility, LH is ordered alongside FSH, total testosterone, and semen analysis. The combination pattern matters: normal LH with low testosterone and azoospermia suggests primary Leydig cell failure; high LH with high FSH and azoospermia suggests Sertoli cell failure or seminiferous tubule damage (Klinefelter syndrome, post-chemotherapy); low LH with low FSH and azoospermia points toward hypothalamic or pituitary cause with potential for recovery using gonadotropin therapy (hMG, FSH plus hCG) [24].

Polycystic Ovary Syndrome

The PCOS guideline published in 2023 by the international collaboration (endorsed by the American Society for Reproductive Medicine) no longer requires an LH-to-FSH ratio above 2:1 for diagnosis, but retains it as a supportive finding [4]. Drugs that lower LH in PCOS (combined oral contraceptives) are used therapeutically to suppress the abnormally high LH pulse frequency characteristic of the condition, which itself drives excess androgen production.